Author:
Murenje Vernon,Omollo Victor,Gonouya Paidemoyo,Hove Joseph,Munyaradzi Tinashe,Marongwe Phiona,Tshimanga Mufuta,Chitimbire Vuyelwa,Xaba Sinokuthemba,Mandisarisa John,Balachandra Shirish,Makunike-Chikwinya Batsirai,Holec Marrianne,Mangwiro Tonderayi,Barnhart Scott,Feldacker Caryl
Abstract
Abstract
Background
Urethrocutaneous fistula (subsequently, fistula) is a rare adverse event (AE) in voluntary medical male circumcision (VMMC) programs. Global fistula rates of 0.19 and 0.28 per 100,000 VMMCs were reported. Management of fistula can be complex and requires expert skills. We describe seven cases of fistula in our large-scale VMMC program in Zimbabwe. We present fistula rates; provide an overview of initial management, surgical interventions, and patient outcomes; discuss causes; and suggest future prevention efforts.
Results
Case details are presented on fistulas identified between March 2013 and October 2019. Among the seven fistula clients, ages ranged from 10 to 22 years; 6 cases were among boys under 15 years of age. All clients received surgical VMMC by trained providers in an outreach setting. Clients presented with fistulae 2–42 days after VMMC. Secondary infection was identified in 6 of 7 cases. Six cases were managed through surgical repair. The number of repair attempts ranged from 1 to 10. One case healed spontaneously with conservative management. Fistula rates are presented as cases/100,000 VMMCs.
Conclusion
Fistula is an uncommon but severe AE that requires clinical expertise for successful management and repair. High-quality AE surveillance should identify fistula promptly and include consultation with experienced urologists. Strengthening provider surgical skills and establishment of standard protocols for fistula management would aid future prevention efforts in VMMC programs.
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Reference34 articles.
1. Reed JB, Njeuhmeli E, Thomas AG, Bacon MC, Bailey R, Cherutich P, et al. Voluntary medical male circumcision: an HIV prevention priority for PEPFAR. J Acquir Immune Defic Syndr. 2012;60 Suppl 3(03):S88–95.
2. Hinkle LE, Toledo C, Grund JM, Byams VR, Bock N, Ridzon R, et al. Bleeding and blood disorders in clients of voluntary medical male circumcision for HIV prevention—eastern and southern Africa, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(11):337–9.
3. World Health Organization. Voluntary medical male circumcision: remarkable progress in the scale up of VMMC as an HIV prevention intervention in 15 ESA countries. In: Voluntary medical male circumcision: remarkable progress in the scale up of VMMC as an HIV prevention intervention in 15 ESA countries. 2019.
4. Bochner AF, Feldacker C, Makunike B, Holec M, Murenje V, Stepaniak A, et al. Adverse event profile of a mature voluntary medical male circumcision programme performing PrePex and surgical procedures in Zimbabwe. J Int AIDS Soc. 2017;20(1):21394.
5. Feldacker C, Bochner AF, Murenje V, Makunike-Chikwinya B, Holec M, Xaba S, et al. Timing of adverse events among voluntary medical male circumcision clients: Implications from routine service delivery in Zimbabwe. PLoS ONE. 2018;13(9):e0203292.